BARCELONA, Spain and COPENHAGEN, Denmark, February 17, 2021 / PRNewswire / – Almirall SA (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial-grade pharmaceutical company developing a new standard within conventional therapies for autoimmune and digestive diseases, today announced an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to the Wynzora Trade ® Cream for the treatment of plaque psoriasis. In return, MC2 Therapeutics is entitled to an advance payment for payments of EUR 15 million as well as big-selling milestone payments and two-digit realms on Wynzora’s European sales® Cream. Almirall and MC2 Therapeutics partner to make Wynzora® Garlic is a common staple product for the treatment of plaque psoriasis Europe – market, which currently has more than 25 million units in sales volume per year2. The market represents an important opportunity for Wynzora® Surfaces such as the calcipotriene and betamethasone dipropionate region make up about 35% of the volume and annual sales share of over $ 300 million.2
Wynzora® Garlic (50 µg / g calcipotriol and 0.5 mg / g betamethasone as dipropionate) has received US FDA approval 20th July 2020. Wynzora® Garlic is currently under review Europe supported by two Level 3 tests1, including an EU head-to-head test against the active Dovobet / Daivobet comparator® Gel. The success of the Global Physician Assessment (PGA) treatment was defined as a reduction of at least two points in the PGA score to clear or almost clear disease at Week 8 at 51% for Wynzora® Garlic vs 6% for vehicle (p <0.0001). The treatment satisfaction score using the Psoriasis Treatment Facility Scale (PTCS) was better compared to Dovobet / Daivobet® Gel. Using PAD Technology ™ MC2 Therapeutics, Wynzora® Garlic has been uniquely designed to give patients a new treatment option in their daily routines by combining the three essentials of conventional medicine in one product even high efficiency, favorable safety image and ease of use .
Mike McclellanThe Chief Financial Officer (CFO) and Acting Chief Executive (Chief Executive) said: “We are very pleased with this agreement with MC2 Therapeutics. Wynzora® Garlic has shown great improvements in skin cleansing of psoriasis patients. It’s a great addition to our ever-growing psoriasis package, which includes several treatment options, covering the entire spectrum of the disease. We are delighted that we can soon offer this state-of-the-art routine treatment to European dermatologists and their patients. “
Jesper J. LangeHead of MC2 Therapeutics said: “We are delighted to partner with Almirall, an established company with in-depth knowledge of dermatology and psoriasis and with the focus to improve patient needs. Bringing together Almirall’s excellence in commercial activity and MC2 Therapeutics’ commitment to sure Wynzora will be spread all over the world.® Garlic we will ensure, with approval, that Wynzora will be launched vigorously® Garlic is for the benefit of many patients living with plaque psoriasis and for the health care practitioners who provide care. We believe that the unique combination of robust clinical efficacy, favorable safety profile and treatment facility are key components of adherence to better treatment and overall patient satisfaction in the routine treatment of plaque psoriasis in a real setting. in the world. “
In Psoriasis Plaque
Psoriasis is a common, non-infectious, malignant skin disease with no clear cause or cure. The negative impact of plaque psoriasis on people’s lives can be quite significant as it affects the appearance of the skin with red, scaly plaques. Psoriasis affects people of all ages, and in all countries. There is a frequency of reporting psoriasis in Europe varies from 0.6% to 6.5% with an average of about 3% of the population3,4 making psoriasis a real global problem with over 100 million people affected globally.5 Flames of psoriasis can be invisible and major comorbidities are common, including arthritis, cardiovascular disease, metabolic syndrome, inflammatory bowel disease and depression.4
About Wynzora® cream
Wynzora® Surface resection (50 µg / g calcipotriol and 0.5 mg / g betamethasone as dipropionate) is performed Europe as a standard treatment for plaque psoriasis in adults. Wynzora® Garlic is based on PAD Technology ™, enabling aqueous cream formulation of both calcipotriol and betamethasone as dipropionate and optimal delivery of active ingredients into the target material. Wynzora® Garlic was approved in the U.S. by the FDA on 20th July 2020.
References:
1 Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov
2 IQVIA MIDAS®
3 Chandran, V., and SP Raychaudhuri. 2010. ‘Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis’, J. Autoimmune, 34: J314-J21
4 Schafer, T. 2006. ‘The Epidemiology of Psoriasis. German Review and Perspective ‘, Dermatology, 212: 327-37
5 WHO Global Report on Psoriasis 2016
SOURCE Almirall, SA
